MyHealthTeam
MyHealthTeam | Posters
Swoop
Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Background People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to treating patients and enabling them to live more fulfilling lives. Objectives To understand the impact of psoriatic arthritis (PsA) and desired treatment outcomes.
MyHealthTeam | Posters
Swoop
Understanding the Impact of Stigma in an Online Community of Hidradenitis Suppurativa Patients
Background People with hidradenitis suppurativa (HS) often experience feelings of stigma.1 This study aimed to assess how they feel about the impact of HS on their sense of self and how they think others perceive them. Objective To evaluate sources of stigma in HS. To evaluate the dynamics and impact of internal and external stigma […]
Eric Peacock
The Rare Disease Marketing Guide: 5 Strategies Every Pharma Marketer Needs To Know for Patient Engagement
R&D in rare diseases has skyrocketed. Thirty percent of today’s R&D pipeline is in rare diseases, and 40 percent of overall pipeline growth since 2013 is due to rare diseases.
MyHealthTeam | Posters
Swoop
Empowering Primary Biliary Cholangitis Patients with Peer Support and Education
Purpose To share a successful example of building a rare disease social network by creating a scalable, connectedcommunity and making patient education readily accessible. Background MyHealthTeam (MHT) has created 61 social networks for people living with chronic health conditions, including 14 rare diseases. The social networks provide individuals living with these conditions an opportunity to […]
MyHealthTeam | Posters
Swoop
Patient Reported Impact of Pulmonary Arterial Hypertension and Desired Treatment Outcomes
Background Patients diagnosed with the rare disease of PAH must deal not only with the physical aspects of PAH, but also the mental health, social, and economic ramifications of this life-changing disease. Understanding the holistic impact of PAH on patients along with patient needs is crucial to enabling them to live more fulfilling lives.
Eric Peacock
AI, Data, and the Future of Health Care Marketing: A Conversation With 4 Pharma Advertising Experts
Health care marketing is rapidly evolving, driven by AI, health privacy legislation, the need to reach more diverse patient communities, and the growth of direct-to-patient offerings. To help us sort the reality from the hype, we invited four brilliant partners from top pharma agencies to join a panel at our recent MyHealthTeam Summer Summit in NYC. Their candid, unfiltered observations are summarized below.
MyHealthTeam | Posters
Swoop
Lung Cancer Patient Reported Experiences With Biomarker Testing
Introduction Research was undertaken to better understand awareness and experiences with biomarker testing among patients living with Non-Small Cell Lung Cancer (NSCLC). Additionally, research sought to understand potential health inequities in terms of access to biomarker testing.
MyHealthTeam | Posters
Swoop
Patient Reported Attitudes Towards Multiple Sclerosis Treatment
Background MS is a progressive disease that can have a devastating impact on quality of life. Yet obstacles exist for getting patients to start on or stay on a DMT to help slow progression. Understanding patient concerns and highlighting the benefits of DMTs can enable neurologists to help their patients overcome usage barriers. Objectives Research […]
Eric Peacock
The New Marketing Playbook: Engaging Patients in the Era of AI, Personalization, Patient Privacy, and Direct-to-Patient Offerings
At MyHealthTeam’s all-company get-together in Nashville, we invited five pharma marketing experts from top agencies and biotechs to join me on a panel. We discussed the “New Marketing Playbook” for everything from rare disease launches to direct-to-patient models to innovative uses of AI with patients.
Swoop
Zero Party and First Party Data Defined for Pharma Marketers
"Data is not created equally. Understanding the difference between zero-party and first-party data can be game-changing for pharma marketers. Below is a guide on how pharma marketers can reach more of the right people with less waste."